Skip to Main Content

Paper Details

Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.
JCO Precis Oncol
26
2019
CONCLUSION, ERBB2, HER2, Human, Human epidermal growth factor receptor 2, PATIENTS, Patients, Solid Tumors, breast and gastric and gastroesophageal junction cancers, breast cancer, colorectal cancer, nonesophageal cancers, nongastric, nongastroesophageal junction,, patients, tumor, tumors
Author NameAffiliation
Kenneth R HessThe University of Texas MD Anderson Cancer Center
Kenneth R HessThe University of Texas MD Anderson Cancer Center
Scott KopetzThe University of Texas MD Anderson Cancer Center
Mark J RoutbortThe University of Texas MD Anderson Cancer Center
Shubham PantThe University of Texas MD Anderson Cancer Center
Jordi RodonThe University of Texas MD Anderson Cancer Center
Kenna R Mills ShawThe University of Texas MD Anderson Cancer Center
Kenna R Mills ShawThe University of Texas MD Anderson Cancer Center
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
  • 1 - 9

Datasets

Release 1.2